BioCatalystWatch
NBPWorkspace / NBP / OverviewCompany library
NovaBridge Biosciences logo

NovaBridge Biosciences

NovaBridge Biosciences (NBP)

Website

Price
Market cap
Next catalystExpected 2H 2026Ragistomig · Phase 1 dataCompany presentation ↗
Cash

Chart & Events

Candle interval

Core Clinical

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

PreINDP1P2P3FilingApproved
Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Givastomig

CLDN18.2 × 4-1BB

Upcoming / outlook

Other pipelines

felzartamab (TJ202/MOR202)

CD38

PreINDP1P2P3FilingApproved
felzartamab (TJ202/MOR202)

CD38

PreINDP1P2P3FilingApproved
lemzoparlimab (TJC4)

CD47

PreINDP1P2P3FilingApproved
lemzoparlimab (TJC4)

CD47

PreINDP1P2P3FilingApproved
Givastomig

CLDN18.2 × 4-1BB

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
TJ-C64B

CLDN6 × 4-1BB

PreINDP1P2P3FilingApproved

Partner / License out

Ragistomig

PD-L1 × 4-1BB

PreINDP1P2P3FilingApproved

History / paused

B7-H3

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status
3M3M

Market Reaction / Supply Context

Market Structure

NBP PR & News

PR & News

NBP SEC archive